Nanotreatment and Nanodiagnosis of Prostate Cancer: Recent Updates.

Nanotreatment and Nanodiagnosis of Prostate Cancer: Recent Updates.
复制标题

DOI:
10.3390/nano10091696
复制
发表时间:
2020-08-28
期刊:
Nanomaterials (Basel, Switzerland)
影响因子:
--
通讯作者:
Kyzas GZ
Kyzas GZ
中科院分区:
其他
文献类型:
--
作者:
Barani M;Sabir F;Rahdar A;Arshad R;Kyzas GZ

文献摘要

参考文献

被引文献

相似文献

近年来,用于前列腺癌治疗的纳米材料的制备和发展得到了广泛的重视。有机和无机纳米材料的合成在电荷、粒径、特定几何形状、配体附着等方面取得了进展,导致了更高的生物相容性和对癌症部位的活性靶向。尽管多年来在发现前列腺癌(PCa)的药物、方法和新的生物标志物方面取得了进展,但前列腺癌仍然是人们最困扰的癌症之一。在早期,有效的诊断是治疗前列腺癌的关键部分。前列腺特异性抗原(PSA)或血清前列腺特异性抗原是诊断前列腺癌的最佳血清标志物。在过去的十年中,人们为设计新的基于生物传感器的生物分子检测和PSA小型化生物标志物的策略做出了许多努力。不断发展的纳米技术预计将在不久的将来对科学研究和医疗保健产生重大影响。因此,预计纳米技术将找到一种方法来解决“早期癌症检测”这一最长期存在的问题之一。对于前列腺癌生物标志物的早期诊断,不同的纳米颗粒和不同的方法被使用。在这篇综述中,我们简要介绍了纳米颗粒用于前列腺癌生物标志物诊断的最新成果和进展。
The fabrication and development of nanomaterials for the treatment of prostate cancer have gained significant appraisal in recent years. Advancements in synthesis of organic and inorganic nanomaterials with charge, particle size, specified geometry, ligand attachment etc have resulted in greater biocompatibility and active targeting at cancer site. Despite all of the advances made over the years in discovering drugs, methods, and new biomarkers for cancer of the prostate (PCa), PCa remains one of the most troubling cancers among people. Early on, effective diagnosis is an essential part of treating prostate cancer. Prostate-specific antigen (PSA) or serum prostate-specific antigen is the best serum marker widely accessible for diagnosis of PCa. Numerous efforts have been made over the past decade to design new biosensor-based strategies for biomolecules detection and PSA miniaturization biomarkers. The growing nanotechnology is expected to have a significant effect in the immediate future on scientific research and healthcare. Nanotechnology is thus predicted to find a way to solve one of the most and long-standing problem, “early cancer detection”. For early diagnosis of PCa biomarkers, different nanoparticles with different approaches have been used. In this review, we provide a brief description of the latest achievements and advances in the use of nanoparticles for PCa biomarker diagnosis.
DOI: 10.1016/j.jddst.2020.101715
发表时间: 2020-06-01
影响因子: 5
作者:
Akbarzadeh, Iman;Yaraki, Mohammad Tavakkoli;Mousavian, Seyede Maryam
通讯作者: Mousavian, Seyede Maryam
DOI: 10.3892/or_00000440
发表时间: 2009-08-01
期刊: ONCOLOGY REPORTS
影响因子: 4.2
作者:
Bode, Christian;Trojan, Lutz;Michel, Maurice Stephan
通讯作者: Michel, Maurice Stephan
DOI: 10.1515/dmpt-2018-0032
发表时间: 2019-03-01
影响因子: --
作者:
Alavi, Mehran;Hamidi, Mehrdad
通讯作者: Hamidi, Mehrdad
DOI: 10.1038/s41379-019-0408-4
发表时间: 2020-05-01
期刊: MODERN PATHOLOGY
影响因子: 7.5
作者:
Cahill, Lucas C.;Wu Yubo;Fujimoto, James G.
通讯作者: Fujimoto, James G.
DOI: 10.1016/j.nantod.2019.06.001
发表时间: 2019-08-01
期刊: NANO TODAY
影响因子: 17.4
作者:
Caracciolo, Giulio;Vali, Hojatollah;Mahmoudi, Morteza
通讯作者: Mahmoudi, Morteza